×
Choose Speciality

EXPLORE!

LOGIN

Risankizumab enhances remission rates in moderate to severe refractory Crohns disease

  1047 Views

eMediNexus    04 August 2018

Extended treatment with 600 mg intravenous risankizumab in patients with moderate to severe, treatment-refractory Crohns disease who were not in deep remission at week 12, increased clinical response and remission rates at week 26, as per a study published in the Lancet Gastroenterology and Hepatology.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.